Ascendis Pharma(ASND) - 2022 Q4 - Annual Report
Ascendis Pharma(ASND)2023-02-15 16:00Exhibit 99.1 LOGO Ascendis Pharma Reports Full Year 2022 Results – TransCon™ PTH PDUFA date of April 30, 2023, for adults with hypoparathyroidism; European MAA decision expected in the fourth quarter of 2023 – Expanding TransCon hGH geographic reach with planned launch in Germany in the third quarter of 2023; Phase 3 data in adult GHD indication expected in the fourth quarter of 2023 – Initiated Phase 2b ApproaCH Trial for TransCon CNP in achondroplasia; expected to complete enrollment in the second quarter ...